期刊文献+

阿魏酸钠注射液治疗瘀血阻络型肝硬化腹水40例疗效观察

Treatment of cirrhosis ascites with obstruction of collaterals by blood stasis by sodium ferulate injection
下载PDF
导出
摘要 目的观察阿魏酸钠注射液治疗瘀血阻络型肝硬化腹水的临床疗效。方法将78例瘀血阻络型肝硬化腹水患者随机分为2组,治疗组40例予阿魏酸钠注射液200 mg,每日1次静脉滴注;对照组38例予丹参注射液20 mL,每日1次静脉滴注。2组均30 d为1个疗程,2个疗程后评定疗效,随访12个月后观察远期效果。结果治疗组总有效率92.5%,对照组总有效率68.4%2,组总有效率比较差异有统计学意义(P<0.05);治疗组治疗后肝功能及B超情况较治疗前均有明显改善(P<0.05),对照组治疗后血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBiL)及门静脉主干内径较本组治疗前均有明显改善(P<0.05);治疗组治疗后AST、白蛋白(Alb)、门静脉主干内径及脾厚改善情况均优于对照组(P<0.05);治疗组治疗后纳差、腹胀、倦怠乏力、寐欠、便秘、便溏、小便少、黄疸、双下肢水肿改善率优于对照组(P<0.05)。结论阿魏酸钠注射液治疗瘀血阻络型肝硬化腹水疗效确切。 Objective To observe the clinical effect of cirrhosis ascites with obstruction of collaterals by blood stasis by sodium ferulate.Methods 78 patients of cirrhosis ascites with obstruction of collaterals by blood stasis were randomly divided into two groups.40 cases in treatment group were treated by intravenous drip of sodium ferulate injection.38 patients in control group were treated by intravenous drip of Danshen injection.The course was 30 days in two groups.The effect was evaluated after two courses.The long-term effect was observed follow-up of 12 months later.Results The total effective rate in treatment group(92.5%) was superior to that in control group(68.4%,P0.05).Hepatic function and type-B ultrasonic after treatment were significantly improved in treatment group(P0.05).ALT,AST,TBiL and inner diameter(ID) of main portal vein(MPV) after treatment were significantly improved in control group(P0.05).The improvement of AST,Alb,ID of MPV and Thickness of spleen in treatment group was superior to that in control group after treatment(P0.05).The improvement of symptoms of traditional Chinese medicine including poor appetite,abdominal distension,Languid and constipation etc in treatment were superior to those in control group after treatment(P0.05).Conclusion Sodium ferulate injection has definite effect on cirrhosis ascites with obstruction of collaterals by blood stasis.
出处 《河北中医》 2010年第12期1855-1857,共3页 Hebei Journal of Traditional Chinese Medicine
基金 广西壮族自治区贺州市科学研制与技术开发计划(编号:贺科攻关0503009)
关键词 丹参 阿魏酸 腹水 肝硬化 并发症 中医药疗法 Salviae miltiorrhizae Ferulaic acid Hydroperitoneum Cirrhosis Complication
  • 相关文献

参考文献8

二级参考文献35

  • 1刘超,刘刚,刘坤申.内皮素受体拮抗剂与肺动脉高压的治疗[J].中国实用内科杂志,2005,25(1):82-83. 被引量:6
  • 2吴东方,彭仁琇,王玉山,汪晖,孔锐.阿魏酸钠对溴苯肝损害的有效作用[J].湖北医科大学学报,1994,15(3):229-233. 被引量:2
  • 3刘天舒.肝硬化腹水[A].王吉耀.现代肝病治疗理论与进展[C].上海:上海医科大学出版社,1999.262.
  • 4Channick RN, Sitbon O, Robbins I, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension : a randomised placebo-controlled study. Lancet, 2001,358(9288) :1119-1123.
  • 5Rubin LJ, Badesch DB, Barst RJ,et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med ,2002,346 (12) :896-903.
  • 6Galie N, Adam T, Thierry F, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol,2003,41 ( 8 ) : 1380-1386.
  • 7Rubens C ,Halank M,Wensel R,et al. Endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest,2001,120 ( 5 ) : 1562-1569.
  • 8Yamamoto K,Ikeda U, Mito H,et al. Endothelin production in pulmonary circulation of patients with mitral stenosis. Circulation,1994,89(5) :2093-2098.
  • 9张乃生,张良东,张良芬.肝硬化顽固性腹水的内科药物治疗[J].实用医技杂志,1997,4(2):151-152. 被引量:1
  • 10Kojima H, Yamao J, Tsujimoto T, et al. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J Hepatal 2000;32: 43-50.

共引文献14705

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部